LANSOPRAZOLE | A207167 | AUROBINDO PHARMA LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
TAKEDA PHARMACEUTICAL COMPANY LIMITED et al v. AUROBINDO PHARMA LTD. et al 4 patentsANDA 207167lansoprazole | D.N.J. | 2015-10-21 | Terminated 2018-05-29 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$2.18
per ea
Lowest NADAC/Unit
$1.66
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 72603031410LANSOPRAZOLE DR 30 MG ODT | $2.18 | EA | Generic | — | 2026-06-17 |
| 65862089678LANSOPRAZOLE DR 30 MG ODT | $2.18 | EA | Generic | — | 2026-06-17 |
| 72603031310LANSOPRAZOLE DR 15 MG ODT | $1.66 | EA | Generic | — | 2026-06-17 |
| 65862089578LANSOPRAZOLE DR 15 MG ODT | $1.66 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.